Citigroup Forecasts Strong Price Appreciation for Attovia Therapeutics (NASDAQ:ATTO) Stock

Attovia Therapeutics (NASDAQ:ATTO) had its target price boosted by investment analysts at Citigroup from $30.00 to $34.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup‘s price target would indicate a potential upside of 108.01% from the company’s previous close.

ATTO has been the subject of several other research reports. Weiss Ratings began coverage on shares of Attovia Therapeutics in a research note on Monday, November 2nd. They issued a “sell (e-)” rating for the company. Lifesci Capital began coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price target for the company. Morgan Stanley boosted their price target on shares of Attovia Therapeutics from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday. Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Zacks Research raised Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.20.

Attovia Therapeutics Price Performance

NASDAQ ATTO traded up $0.39 during trading hours on Tuesday, reaching $16.34. The company had a trading volume of 82,246 shares, compared to its average volume of 346,537. The company has a market capitalization of $746.15 million and a PE ratio of -3.32. The firm has a 50-day moving average price of $18.06. Attovia Therapeutics has a 1-year low of $12.94 and a 1-year high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). During the same quarter last year, the firm earned ($3.44) EPS. Attovia Therapeutics’s revenue for the quarter was down 100.0% compared to the same quarter last year. As a group, research analysts forecast that Attovia Therapeutics will post -4.06 EPS for the current fiscal year.

Attovia Therapeutics Company Profile

Attovia Therapeutics is a clinical-stage biotechnology company developing medicines for inflammatory and immune-mediated diseases. Its research focuses on antibody-based therapies intended to address biological pathways involved in these conditions. The company’s programs are in development, and its work centers on discovering and advancing potential treatments rather than marketing established products. Attovia Therapeutics is listed on the Nasdaq under the symbol ATTO. Publicly available information about the company’s history, leadership and geographic operations is limited.